echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > First FDA Approves Innovative Insomnia Therapies Today in 2022

    First FDA Approves Innovative Insomnia Therapies Today in 2022

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 10, 2022, Idorsia announced that the U.


    This approval is based on positive results from a Phase 3 clinical program


    The primary efficacy endpoints of both trials were the change in time required to enter sustained sleep (LPS) and wake after sleep onset (WASO) from baseline to months 1 and 3


    ▲ Orexin stimulates multiple signaling pathways that promote wakefulness (Image source: Reference [2])

    Results of the Phase 3 clinical program showed that Quviviq at a dose of 50 mg significantly improved objective measures of sleep onset and sleep maintenance, as well as patient-reported total sleep time, compared with placebo


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.